KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Gains from Sales and Divestitures: 2018-2020

Historic Gains from Sales and Divestitures for Aquestive Therapeutics (AQST) over the last 2 years, with Dec 2020 value amounting to $64,000.

  • Aquestive Therapeutics' Gains from Sales and Divestitures fell 48.80% to $64,000 in Q4 2020 from the same period last year, while for Dec 2020 it was $64,000, marking a year-over-year decrease of 48.80%. This contributed to the annual value of $64,000 for FY2020, which is 48.80% down from last year.
  • As of Q4 2020, Aquestive Therapeutics' Gains from Sales and Divestitures stood at $64,000, which was down 0.00% from $64,000 recorded in Q3 2020.
  • Over the past 5 years, Aquestive Therapeutics' Gains from Sales and Divestitures peaked at $125,000 during Q4 2019, and registered a low of $29,802 during Q3 2018.
  • In the last 3 years, Aquestive Therapeutics' Gains from Sales and Divestitures had a median value of $60,000 in 2020 and averaged $61,680.
  • Per our database at Business Quant, Aquestive Therapeutics' Gains from Sales and Divestitures skyrocketed by 218.77% in 2019 and then tumbled by 48.80% in 2020.
  • Quarterly analysis of 3 years shows Aquestive Therapeutics' Gains from Sales and Divestitures stood at $60,000 in 2018, then skyrocketed by 108.33% to $125,000 in 2019, then slumped by 48.80% to $64,000 in 2020.
  • Its Gains from Sales and Divestitures stands at $64,000 for Q4 2020, versus $64,000 for Q3 2020 and $60,000 for Q2 2020.